Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/32329
Type
ArticleCopyright
Restricted access
Embargo date
2022-01-01
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
- IOC - Artigos de Periódicos [12973]
Metadata
Show full item record
NEW VACCINES AGAINST TUBERCULOSIS: LESSONS LEARNED FROM BCG IMMUNISATION IN BRAZIL
Affilliation
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ. Brasil.
Abstract
The current tuberculosis (TB) vaccine Mycobacterium bovis BCG has been employed
for some 70 years in Brazil and lessons from its use should be taken in account for the development
or improvement of new TB vaccines. The vast majority of the current population has been
vaccinated with BCG, with the possible requirement for a booster immunisation in adulthood for
TB protection. BCG Moreau strain also protects against leprosy, meningitis and extrapulmonary
forms of TB. Factors related to differences in strain, dosage and BCG administering protocol
have been responsible for the variable efficacy of BCG. This vaccine is clearly affected by, as
yet unclear, host and/or environmental variables. In this brief review, we describe some aspects
of BCG immunisation observed in Brazil that may be of importance for improving or replacing
BCG.
Share